lassa
viru
lasv
caus
lassa
hemorrhag
fever
human
pose
signific
threat
public
health
west
africa
current
therapeut
treatment
lassa
fever
limit
make
develop
novel
countermeasur
urgent
prioriti
studi
identifi
losmapimod
mitogenactiv
protein
kinas
mapk
inhibitor
screen
compound
inhibitor
lasv
infect
losmapimod
exert
inhibitori
effect
lasv
mapk
downregul
interestingli
effect
arenavirus
capabl
caus
viral
hemorrhag
fever
mechanist
studi
show
losmapimod
inhibit
lasv
entri
affect
stabl
signal
peptid
ssp
subunit
interfac
lasv
glycoprotein
therebi
block
phdepend
viral
fusion
aryl
heteroaryl
biscarboxyamid
deriv
losmapimod
repres
novel
chemic
scaffold
antilasv
activ
provid
new
lead
structur
futur
develop
lasv
fusion
inhibitor
lasv
along
prototyp
arenaviru
lymphocyt
choriomening
viru
lcmv
lujo
viru
lujv
belong
old
world
mammarenavirus
radoshitzki
et
al
new
world
complex
also
contain
sever
virus
caus
viral
hemorrhag
fever
vhf
human
includ
machupo
viru
macv
guanarito
viru
gtov
junin
viru
junv
sabia
viru
sabv
chapar
viru
chpv
sarut
ross
lasv
phylogenet
closer
lcmv
new
world
mammarenavirus
oldston
lasv
envelop
rna
viru
contain
two
ambisens
rna
genom
segment
encod
viral
polymeras
l
matrix
protein
z
nucleoprotein
np
glycoprotein
complex
gpc
knipe
howley
lasv
entri
mediat
sole
gpc
first
synthes
singl
polypeptid
cleav
signal
peptidas
proteas
three
segment
stabl
signal
peptid
ssp
receptorbind
subunit
membran
fusion
subunit
bederka
et
al
ssp
noncoval
bound
togeth
form
trimer
pack
onto
virion
surfac
bederka
et
al
ssp
consist
amino
acid
two
transmembran
domain
one
ectodomain
bederka
et
al
subunit
associ
receptor
recognit
interact
cellular
receptor
alphadystroglycan
acciani
et
al
lysosomeassoci
membran
protein
jae
et
al
subunit
class
viral
fusion
protein
upon
exposur
acid
environ
undergo
conform
chang
trigger
membran
fusion
igonet
et
al
ssp
essenti
gpc
matur
burri
et
al
promot
gpcmediat
phdepend
membran
fusion
interact
subunit
messina
et
al
lasv
one
categori
agent
requir
biosafeti
level
contain
center
diseas
control
prevent
pose
signific
obstacl
antivir
discoveri
use
recombin
pseudotyp
viru
system
therefor
accept
altern
antivir
screen
larson
et
al
tani
et
al
chen
et
al
fact
number
arenaviru
entri
inhibitor
broadspectrum
arenaviru
entri
inhibitor
larson
et
al
lujo
viru
entri
inhibitor
desipramin
tani
et
al
discov
pseudoviru
screen
spread
lassa
fever
africa
lack
efficaci
therapeut
impos
dire
need
antivir
develop
drug
repurpos
becom
popular
field
aim
fasttrack
develop
process
ashburn
thor
strategi
wide
use
identifi
ebola
zika
sever
acut
respiratori
syndrom
sar
viru
inhibitor
sever
promis
hitleadantivir
report
cheng
et
al
dyall
et
al
johansen
et
al
kouznetsova
et
al
madrid
et
al
lacidipin
identifi
approv
drug
librari
compound
antilasv
activ
wang
et
al
studi
examin
clinic
compound
librari
search
lasv
inhibitor
identifi
losmapimod
mitogenactiv
protein
kinas
mapk
inhibitor
origin
intend
cardiovascular
diseas
chronic
obstruct
pulmonari
diseas
copd
inhibitor
lasv
entri
hela
mg
vero
cell
obtain
china
infrastructur
cell
line
resourc
beij
china
vero
cell
obtain
american
type
cultur
collect
atcc
cell
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
usa
supplement
fb
iuml
penicillin
streptomycin
mg
cell
cultur
minim
essenti
medium
mem
invitrogen
carlsbad
ca
usa
supplement
fetal
bovin
serum
fb
gibco
usa
iuml
penicillin
streptomycin
cell
maintain
humidifi
atmospher
contain
co
codonoptim
gpc
gene
lasv
strain
josiah
genbank
access
strain
lp
genbank
access
strain
genbank
access
strain
genbank
access
lcmv
strain
armstrong
genbank
access
lujv
genbank
access
macv
strain
carvallo
genbank
access
gtov
strain
genbank
access
junv
strain
genbank
access
sabv
strain
genbank
access
wwav
strain
genbank
access
chpv
strain
genbank
access
yp
synthes
insert
eukaryot
express
vector
describ
previous
zhang
et
al
envdefici
hiv
core
plasmid
e
obtain
nation
institut
health
aid
research
refer
reagent
program
germantown
md
usa
clinic
compound
librari
obtain
targetmol
boston
usa
compound
guarante
pure
losmapimod
puriti
desipramin
hydrochlorid
puriti
obtain
targetmol
puriti
obtain
medchemexpress
nj
usa
puriti
obtain
life
chemic
woodbridg
ct
usa
bafilomycin
puriti
obtain
lc
laboratori
boston
usa
compound
puriti
provid
supplier
compound
dissolv
dimethyl
sulfoxid
dmso
sigma
st
loui
mo
usa
store
use
dmso
use
vehicl
control
experi
final
concentr
evalu
effect
compound
cell
viabil
celltiterglo
luminesc
cell
viabil
assay
promega
madison
wi
usa
perform
previous
describ
briefli
cell
treat
final
concentr
compound
cell
viabil
serial
dilut
compound
half
maxim
cytotox
concentr
cc
assess
plate
format
start
cell
densiti
cellswel
fortyeight
hour
later
celltiterglo
assay
perform
rel
luminesc
unit
rlu
record
cell
treat
dmso
vv
serv
solvent
control
mean
rlu
valu
set
cell
viabil
doxorubicin
use
posit
control
cell
medium
serv
neg
control
percentag
cell
viabil
calcul
follow
rlu
compoundrlu
dmso
control
assay
perform
triplic
well
compound
concentr
mean
standard
deviat
sd
calcul
graphpad
prism
softwar
cell
viabil
also
evalu
vero
cell
use
losmapimod
concentr
rang
briefli
vero
cell
seed
plate
day
assay
cell
treat
compound
indic
concentr
incub
h
cell
viabil
evalu
use
assay
kit
roch
cat
cell
medium
use
neg
control
dmso
vv
serv
solvent
control
puromycin
use
posit
control
describ
previous
percentag
cell
viabil
calcul
follow
ru
compoundru
dmso
control
assay
perform
triplic
well
compound
concentr
mean
standard
deviat
sd
calcul
graphpad
prism
softwar
hiv
pseudotyp
virus
bear
glycoprotein
gp
nine
arenavirus
gener
use
viru
infect
assay
compound
activ
assay
previous
report
zhang
et
al
briefli
plasmid
encod
arenavirusgp
hiv
vector
e
cotransfect
cell
h
later
arenavirusgphivluc
collect
quantifi
elisa
kit
sino
biolog
inc
beij
china
store
use
viru
infect
assay
cell
infect
pseudovirus
h
later
viru
infect
measur
luciferas
assay
system
promega
madison
wi
usa
compound
activ
assay
cell
treat
compound
min
prior
arenavirusgphivluc
infect
cell
treat
dmso
vv
serv
solvent
control
rlu
valu
set
infect
assay
perform
duplic
well
viru
infect
compound
concentr
mean
standard
deviat
sd
calcul
graphpad
prism
softwar
vero
cell
pretreat
losmapimod
dmso
h
infect
multipl
infect
moi
wild
type
vesicular
stomat
viru
express
enhanc
green
fluoresc
protein
egfp
vsvegfp
recombin
vsv
lack
nativ
glycoprotein
express
instead
lasvgp
strain
josiah
along
egfp
presenc
drug
dmso
h
follow
incub
inoculum
remov
replac
fresh
medium
dmem
contain
fb
cell
incub
h
presenc
drug
dmso
monitor
evo
fl
microscop
gfp
signal
quantifi
biotek
synergi
htx
plate
reader
assay
perform
duplic
well
compound
doserespons
curv
gener
graphpad
prism
softwar
work
infecti
live
viru
perform
contain
level
facil
nation
microbiolog
laboratori
nml
public
health
agenc
canada
phac
canadian
scienc
centr
human
anim
health
cschah
winnipeg
canada
procedur
conduct
accord
protocol
appropri
level
biosafeti
briefli
vero
cell
grown
plate
confluenc
pretreat
serial
dilut
losmapimod
h
follow
pretreat
cell
infect
lasv
strain
josiah
moi
presenc
drug
h
inoculum
remov
replac
fresh
medium
contain
drug
fb
h
post
infect
cell
cultur
supernat
harvest
viral
titrat
determin
rtqpcr
describ
previous
calcul
tissu
cultur
infecti
dose
tcid
use
reed
muench
method
reed
muench
assay
perform
triplic
well
compound
doserespons
curv
gener
graphpad
prism
softwar
cell
grown
plate
confluenc
cotransfect
sirna
sirna
sirna
synthes
genepharma
suzhou
china
mock
transfect
transfect
reagent
jetprim
polyplu
illkirch
franc
twentyfour
hour
posttransfect
cell
passag
plate
sixti
hour
post
transfect
cell
infect
lasvgp
strain
josiah
hivluc
duplic
well
luciferas
activ
test
h
post
infect
h
posttransfect
infect
cell
test
express
western
blot
rabbit
mapk
polyclon
antibodi
cat
cell
signal
technolog
danver
usa
mous
monoclon
antibodi
origen
technolog
inc
rockvil
md
usa
infect
lasv
pseudoviru
knockdown
cell
normal
mock
set
infect
timeofaddit
assay
mg
cell
incub
lasvgp
strain
josiah
hivluc
h
permit
attach
supernat
contain
unattach
virion
remov
fresh
medium
contain
fb
ad
well
losmapimod
bafilomycin
nm
solvent
control
dmso
vv
ad
cell
preattach
attach
postattach
attach
postattach
lasvgphivluc
cell
incub
co
incub
day
cell
lyse
luciferas
activ
measur
luciferas
assay
system
assay
perform
duplic
well
compound
concentr
mean
standard
deviat
calcul
graphpad
prism
softwar
cell
cotransfect
lasvgp
strain
josiah
express
plasmid
pegfp
lcmvgp
express
plasmid
pegfp
use
jetprim
transfect
reagent
accord
manufactur
protocol
polyplu
illkirch
franc
transfect
cell
seed
plate
h
posttransfect
twentyfour
hour
later
transfect
cell
treat
pb
ph
min
losmapimod
bafilomycin
ad
cell
triplic
well
h
low
ph
treatment
low
ph
treatment
lowph
treatment
h
cell
wash
pb
ph
low
ph
treatment
cell
replenish
fresh
medium
contain
fb
four
hour
later
syncytium
format
observ
fluoresc
microscop
rna
polymerasebas
luciferas
report
cellcel
fusion
assay
also
perform
briefli
cell
cotransfect
rna
polymeras
express
plasmid
lasvgp
strain
josiah
express
plasmid
mg
cell
transfect
firefli
luciferas
express
plasmid
control
promot
twentyfour
hour
posttransfect
cell
passag
cocultur
plate
mg
cocultur
cell
treat
compound
prior
low
ph
treatment
pb
ph
cell
wash
pb
ph
low
ph
treatment
h
later
cell
lyse
luciferas
activ
determin
cell
treat
dmso
use
fusion
assay
perform
triplic
well
compound
concentr
mean
standard
deviat
calcul
graphpad
prism
softwar
lasvgp
strain
josiah
genbank
access
fragment
replac
lcmvgp
strain
genbank
access
creat
overlap
pcr
fusion
peptid
fp
nt
nt
lcmvgp
open
read
frame
amplifi
pcr
fuse
replac
correspond
lasvgp
region
fp
nt
nt
get
lasvgpfpmut
stabl
signal
peptid
ssp
nt
x
zhang
et
al
antivir
research
nt
transmembran
domain
tm
nt
nt
lcmvgp
open
read
frame
amplifi
pcr
fuse
replac
correspond
lasvgp
region
ssp
nt
nt
tm
nt
nt
get
lasvssptmmut
construct
lasvgpfpmut
lasvssptmmut
use
produc
hiv
base
pseudovirus
mutant
virus
use
compound
activ
assay
describ
section
mean
valu
standard
deviat
sd
half
maxim
effect
concentr
ec
valu
calcul
graphpad
prism
softwar
data
analyz
statist
signific
use
student
ttest
asterisk
repres
signific
differ
p
p
librari
compound
variou
stage
clinic
trial
screen
antilasv
strain
josiah
activ
fig
tabl
compound
first
test
final
concentr
cytotox
use
celltiterglo
assay
compound
caus
reduct
cell
viabil
exclud
remaind
studi
rest
compound
test
inhibitori
effect
lasv
use
hiv
pseudotyp
viru
lasvgphivluc
cell
treat
compound
min
prior
lasvgphivluc
infect
compound
inhibitori
effect
calcul
h
post
infect
relat
solvent
control
dmso
vv
initi
screen
five
compound
show
inhibitori
activ
lasvgphivluc
tabl
vesicular
stomat
viru
vsv
glycoprotein
pseudotyp
hiv
vsvghivluc
use
exclud
compound
target
hivluc
core
end
losmapimod
fig
compound
specif
inhibitori
effect
lasvgphivluc
exhibit
ec
fig
losmapimod
also
test
use
recombin
vsv
pseudotyp
model
similar
result
obtain
fig
use
authent
viru
infect
assay
essenti
confirm
compound
activ
studi
authent
lasv
strain
josiah
infect
assay
conduct
losmapimod
exhibit
activ
lasv
infect
vero
cell
assess
tcid
rtqpcr
ec
valu
respect
fig
data
compar
observ
use
lasvgphivluc
demonstr
losmapimod
effect
inhibit
authent
lasv
test
whether
activ
losmapimod
cell
type
specif
losmapimod
test
cell
line
origin
differ
tissu
lung
liver
kidney
etc
anim
speci
human
hamster
monkey
result
show
losmapimod
effect
cell
line
test
fig
indic
antilasv
effect
drug
celltyp
specif
togeth
data
suggest
losmapimod
capabl
inhibit
lasv
infect
directli
block
viral
entri
lasv
strain
josiah
member
lineag
iv
lasv
bowen
et
al
test
efficaci
losmapimod
strain
lasv
belong
differ
lineag
gener
three
addit
hiv
pseudotyp
virus
express
lasvgp
repres
distinct
lineag
strain
lp
lineag
strain
lineag
ii
strain
lineag
iii
losmapimod
show
inhibitori
effect
three
virus
similar
observ
lasv
strain
josiah
ec
valu
rang
tabl
fig
data
suggest
losmapimod
capabl
inhibit
multipl
differ
strain
lasv
sinc
lasv
old
world
arenaviru
caus
viral
hemorrhag
fever
human
next
ask
whether
losmapimod
also
abil
inhibit
arenavirus
caus
human
diseas
eight
arenavirus
includ
two
old
world
arenavirus
lcmv
lujo
viru
six
vhfcaus
new
world
arenavirus
test
sensit
losmapimod
use
hivbas
pseudotyp
arenavirus
arenavirusgphivluc
includ
lcmvgp
hivluc
lujvgphivluc
macvgphivluc
gtovgphivluc
junvgphivluc
sabvgphivluc
wwavgphivluc
chpvgphivluc
use
infect
cell
presenc
losmapimod
shown
tabl
highest
concentr
test
losmapimod
preferenti
inhibit
lasv
among
arenavirus
doserespons
curv
losmapimod
eight
arenavirus
shown
fig
losmapimod
initi
develop
mapk
inhibitor
intend
treatment
cardiovascular
diseas
copd
mapk
class
mitogenactiv
protein
kinas
respons
stress
stimuli
cytokin
ultraviolet
irradi
heat
shock
involv
cell
differenti
apoptosi
autophagi
segal
et
al
four
mapk
identifi
includ
losmapimod
select
inhibitor
ec
valu
submicromolar
rang
norman
determin
whether
antilasv
effect
losmapimod
mediat
mapk
repress
test
infect
lasvgphivluc
knockdown
cell
shown
fig
knockdown
mapk
express
cotransfect
sirna
hinder
lasvgphivluc
infect
activ
losmapimod
unaffect
moreov
three
mapk
inhibitor
assess
antilasv
activ
none
display
inhibitori
activ
lasvgphivluc
infect
tabl
thu
result
indic
antilasv
activ
losmapimod
achiev
inhibit
mapk
lasv
entri
initi
recognit
bind
cellular
receptor
follow
endocytosi
low
phtrigger
membran
fusion
identifi
step
losmapimod
exert
effect
timeofaddit
assay
perform
tai
et
al
losmapimod
incub
cell
preattach
attach
postattach
postattach
lasvgphivluc
fig
viru
infect
determin
h
post
infect
similar
broadli
activ
fusion
inhibitor
bafilomycin
vacuolartyp
h
atpas
vatpas
inhibitor
block
endosom
acidif
losmapimod
inhibit
lasv
infect
postattach
stage
fig
indic
take
effect
viral
fusion
step
recognit
bind
lasv
undergo
macropinocytosi
follow
conform
chang
trigger
high
proton
concentr
endosom
opplig
et
al
conform
chang
lead
exposur
hydrophob
fusion
peptid
result
fusion
viral
endolysosom
membran
white
whittak
examin
whether
losmapimod
could
directli
inhibit
lasvgp
mediat
fusion
cellcel
fusion
assay
perform
cell
express
lasvgp
lcmvgp
green
fluoresc
protein
gfp
subject
lowph
treatment
syncytium
format
observ
fluoresc
microscopi
known
viral
fusion
inhibitor
target
larson
et
al
lcmvspecif
fusion
inhibitor
ngo
et
al
two
compound
use
control
fusion
assay
mention
vacuolartyp
h
atpas
vatpas
inhibitor
bafilomycin
abl
block
lasv
entri
prevent
acidif
endolysosom
pathway
fig
unabl
block
celltocel
membran
fusion
trigger
directli
high
extracellular
proton
concentr
thu
use
neg
control
fusion
assay
fig
shown
fig
losmapimod
inhibit
fusion
mediat
lasvgp
lcmvgp
consist
compound
specif
display
tabl
result
observ
rna
polymerasebas
luciferas
report
cellcel
fusion
assay
fig
assay
losmapimod
dosedepend
inhibit
report
gene
express
driven
polymeras
function
syncytium
form
lasvgp
mediat
cellcel
fusion
timeofaddit
assay
cellcel
fusion
assay
result
togeth
show
losmapimod
act
similarli
suggest
losmapimod
block
viral
fusion
process
affect
conform
arenaviru
gp
complex
form
noncoval
interact
ssp
subunit
phsens
critic
viral
fusion
process
determin
losmapimod
act
lasv
interact
creat
lasvgp
construct
specif
region
replac
correspond
region
lcmvgp
close
resembl
lasvgp
insensit
losmapimod
shown
fig
lasvgpfp
mutant
construct
replac
lasvgp
fusion
peptid
lasvgp
number
lcmv
fusion
peptid
lcmvgp
number
lasvgpssptm
mutant
construct
replac
lasvgpssp
lasvgp
number
lasvgptm
lasvgp
number
lcmvgpssp
statist
signific
two
group
calcul
student
ttest
use
graphpad
prism
softwar
statist
signific
set
p
p
ns
signific
p
prior
low
ph
trigger
four
hour
follow
low
ph
treatment
cell
lyse
luciferas
activ
determin
cell
treat
dmso
vv
use
fusion
experi
repeat
similar
result
obtain
statist
signific
two
group
calcul
student
ttest
use
graphpad
prism
softwar
statist
signific
set
p
p
ns
signific
p
lcmvgp
number
lcmvgptm
lcmvgp
number
lasvlcmvgp
mutant
construct
use
produc
hivbas
pseudotyp
virus
use
test
losmapimod
activ
use
refer
compound
act
ssptm
region
lasvgp
lcmvgp
respect
shown
fig
consist
previous
publish
result
larson
et
al
ngo
et
al
lasv
inhibitor
retain
activ
lasvgpwthivluc
lasvgp
lyse
luciferas
activ
measur
dmso
solvent
control
set
infect
statist
signific
compound
treatment
dmso
calcul
student
ttest
statist
signific
set
p
p
ec
valu
calcul
graphpad
prism
softwar
fpmuthivluc
ineffect
inhibit
lcmvgpwt
lasvgpssptmmuthivluc
convers
lcmv
specif
inhibitor
ineffect
inhibit
lasvgpwthivluc
lasvgpfpmuthivluc
although
remain
activ
lcmvgpwthivluc
lasvgpssptmmuthivluc
shown
fig
similar
activ
losmapimod
lasvgpfpmut
hivluc
compar
lasvgpwthivluc
indic
fusion
peptid
region
target
losmapimod
consequenti
losmapimod
ineffect
lasvgpssptmmuthivluc
infect
suggest
ssptm
region
lasvgp
losmapimod
exert
function
lack
approv
effect
therapeut
lassa
hemorrhag
fever
creat
dire
need
discoveri
new
antivir
drug
repurpos
becom
attract
approach
antivir
discoveri
develop
recent
year
ashburn
thor
losmapimod
develop
oral
mapk
inhibitor
treatment
copd
cardiovascular
diseas
phase
iiiii
clinic
investig
knockdown
assay
show
inhibitori
effect
losmapimod
lasv
entri
depend
upon
regul
origin
therapeut
target
mapk
consid
whether
losmapimod
inhibit
lasv
entri
interact
cellular
receptor
arenavirus
employ
differ
cellular
receptor
entri
new
world
arenavirus
use
human
transferrin
receptor
sarut
ross
lujo
viru
old
world
arenaviru
use
entri
raaben
et
al
convers
lcmv
prototyp
arenaviru
belong
old
world
serotyp
use
receptor
entri
lasv
cao
et
al
among
nine
arenavirus
test
studi
losmapimod
display
activ
lasv
sinc
losmapimod
inhibit
entri
lasv
lcmv
despit
fact
two
virus
share
cellular
receptor
postul
losmapimod
target
cell
surfac
receptor
rather
lasv
gpc
fact
losmapimod
could
directli
inhibit
lasvgp
mediat
fusion
artifici
extracellular
low
ph
condit
suggest
inhibitori
effect
losmapimod
lasv
fusion
achiev
affect
proton
influx
instead
data
impli
direct
interact
lasv
glycoprotein
uniqu
interfac
arenaviru
glycoprotein
crucial
viral
fusion
therefor
attract
target
antivir
mani
previous
discov
arenaviru
entri
inhibitor
lacidipin
target
sensit
domain
shankar
et
al
thoma
et
al
wang
et
al
york
et
al
fragment
replac
mutat
studi
lasvgp
lcmvgp
demonstr
losmapimod
also
target
interfac
interestingli
losmapimod
show
rel
similar
inhibitori
activ
among
four
strain
lasv
less
efficaci
lasv
strain
lp
tabl
fig
sequenc
analys
reveal
gp
lasv
strain
lp
possess
isoleucin
posit
within
tm
region
wherea
gp
three
lasv
strain
possess
valin
posit
fig
suggest
amino
acid
posit
play
critic
role
resist
consist
previou
report
larson
et
al
also
impli
mode
function
losmapimod
differ
sequenc
variat
within
ssp
region
affect
losmapimod
activ
previou
studi
demonstr
mutat
within
ssp
tm
region
confer
resist
drug
lacidipin
wang
et
al
larson
et
al
interest
determin
whether
similar
mutat
aris
respons
treatment
losmapimod
major
benefit
drug
repurpos
compar
tradit
de
novo
discoveri
process
high
success
rate
due
avail
safeti
data
clinic
studi
ashburn
thor
repurpos
drug
dose
regimen
new
applic
often
requir
compar
lower
origin
therapeut
dose
studi
efficaci
losmapimod
lasv
vitro
ec
fig
potent
origin
target
mapk
ec
nm
tabl
make
difficult
repurpos
losmapimod
treatment
lassa
hemorrhag
fever
howev
aryl
heteroaryl
biscarboxyamid
deriv
structur
distinct
lasv
fusion
inhibitor
losmapimod
also
cation
amphiphil
drug
cad
logp
funk
krise
potenti
enabl
accumul
endolysosom
compart
display
antilasv
fusion
effect
inde
uniqu
structur
characterist
make
losmapimod
valuabl
lead
futur
develop
antilasv
agent
author
declar
conflict
interest
